Prostate and other male cancers

Drug Name

• Active Surveillance for Low-Risk Prostate Cancer Safe for Younger Men
• Advanced, Fatal Prostate Cancer Linked to High Visceral Fat
• Agent Orange Possibly Protective in Prostate Cancer ADT Recipients
• AKEEGA
• Biparametric MRI May Suffice for Prostate Cancer Detection
• Bleomycin
• CAMCEVI
• CASODEX
• Cisplatin
• COSMEGEN
• CRPC Linked to Increased Risk for Second Primary Malignancies
• Darolutamide Granted Priority Review Status for nmCRPC
• DELESTROGEN
• ELIGARD
• EMCYT
• ERLEADA
• ESTRACE
• ETOPOPHOS
• FIRMAGON
• Flutamide
• High Gleason Pattern at PSM Ups Prostate Cancer Relapse Risk
• IFEX
• JEVTANA
• Leuprolide acetate
• Long-Term PCa Treatment Outcomes Superior With Radiation Plus ADT
• Long-Term Use of Low-Dose Aspirin May Lower PCa Mortality
• LUPRON DEPOT 7.5mg
• LUPRON DEPOT-3 MONTH 22.5mg
• LUPRON DEPOT-4 MONTH 30mg
• LUPRON DEPOT-6 MONTH 45mg
• LYNPARZA
• MENEST
• Metastasis Site Affects Risk of Dying From Testicular Germ Cell Cancer
• Mitoxantrone HCl
• NILANDRON
• NUBEQA
• ORGOVYX
• PLUVICTO
• PREMARIN
• Prostate Cancer Death Risk Lower With Statin Use After ADT Start
• Prostate Cancer Incidence Dropping, Stable in Most Countries
• Prostate Cancer Mortality Lowest With Radical Prostatectomy
• Prostate mpMRI May Be Helpful in the Neoadjuvant PCa Therapy Setting
• PROVENGE
• Radical Surgery for Metastatic Prostate Cancer Results in Greater Morbidity
• RUBRACA
• TALZENNA
• TAXOTERE
• Time from Definitive Therapy to ADT Predicts mCRPC Risk
• TOPOSAR
• TRELSTAR
• TRT Reduces Post-RARP Recurrence Risk in Low-Risk Prostate Cancer
• TRT Speeds Potency Recovery After Prostate Surgery
• Unique Drug Cuts CRPC Mets Risk
• Vinblastine For Injection
• Vinblastine Injection
• XOFIGO
• XTANDI
• YONSA
• ZOLADEX
• ZOLADEX 3-MONTH 10.8mg
• ZYTIGA